-
前列腺癌(prostate cancer,PCa)是全球男性第二常见的恶性肿瘤,国际癌症研究机构统计结果显示,2020年全球有近140万新发PCa病例和37.5万PCa病死病例[1]。由于医疗水平不断进步和疾病早期筛查的普及,PCa患者的病死率也在不断下降[2]。近年来,随着对前列腺特异性膜抗原(prostate-specific membrane antigen,PSMA)的深入研究,经放射性核素标记后的PSMA应用于PET,其在PCa的分期、指导治疗方案和改善患者预后方面发挥着重要作用。
前列腺特异性膜抗原PET在前列腺癌诊疗中的研究进展
Research progress of prostate specific membrane antigen PET in prostate cancer diagnosis and treatment
-
摘要: 前列腺癌(PCa)是男性最常见的泌尿系统肿瘤。前列腺特异性膜抗原(PSMA)在PCa中的表达具有特异性。放射性核素标记的 PSMA PET在PCa的早期诊断、分期和治疗中具有独特优势。笔者就PSMA PET在PCa诊疗中的最新研究进展进行综述。
-
关键词:
- 前列腺肿瘤 /
- 正电子发射断层显像术 /
- 前列腺特异性膜抗原
Abstract: Prostate cancer (PCa) is the most common urinary tumor in men. Prostate specific membrane antigen (PSMA) is specific in PCa expression. Radionuclide labeled PSMA PET has unique advantages in early diagnosis, staging and treatment of PCa. This paper reviews the latest research progress of PSMA PET in the diagnosis and treatment of PCa. -
[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209−249. DOI: 10.3322/caac.21660. [2] Culp MB, Soerjomataram I, Efstathiou JA, et al. Recent global patterns in prostate cancer incidence and mortality rates[J]. Eur Urol, 2020, 77(1): 38−52. DOI: 10.1016/j.eururo.2019.08.005. [3] Ristau BT, O'Keefe DS, Bacich DJ. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research[J]. Urol Oncol, 2014, 32(3): 272−279. DOI: 10.1016/j.urolonc.2013.09.003. [4] Chang SS, O'Keefe DS, Bacich DJ, et al. Prostate-specific membrane antigen is produced in tumor-associated neovasculature[J]. Clin Cancer Res, 1999, 5(10): 2674−2681. [5] Marchal C, Redondo M, Padilla M, et al. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia[J]. Histol Histopathol, 2004, 19(3): 715−718. DOI: 10.14670/HH-19.715. [6] O'Keefe DS, Bacich DJ, Huang SS, et al. A perspective on the evolving story of PSMA biology, PSMA-based imaging, and endoradiotherapeutic strategies[J]. J Nucl Med, 2018, 59(7): 1007−1013. DOI: 10.2967/jnumed.117.203877. [7] Eiber M, Weirich G, Holzapfel K, et al. Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer[J]. Eur Urol, 2016, 70(5): 829−836. DOI: 10.1016/j.eururo.2015.12.053. [8] Chen MX, Zhang Q, Zhang CW, et al. Combination of 68Ga-PSMA PET/CT and multiparametric MRI improves the detection of clinically significant prostate cancer: a lesion-by-lesion analysis[J]. J Nucl Med, 2019, 60(7): 944−949. DOI: 10.2967/jnumed.118.221010. [9] Donato P, Roberts MJ, Morton A, et al. Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions "invisible" on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology[J]. Eur J Nucl Med Mol Imaging, 2019, 46(1): 20−30. DOI: 10.1007/s00259-018-4160-7. [10] Richenberg J, Løgager V, Panebianco V, et al. The primacy of multiparametric MRI in men with suspected prostate cancer[J]. Eur Radiol, 2019, 29(12): 6940−6952. DOI: 10.1007/s00330-019-06166-z. [11] Donato P, Morton A, Yaxley J, et al. 68Ga-PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: is 68Ga-PSMA PET/CT guided biopsy the future?[J]. Eur J Nucl Med Mol Imaging, 2020, 47(8): 1843−1851. DOI: 10.1007/s00259-019-04620-0. [12] Kalapara AA, Nzenza T, Pan HYC, et al. Detection and localisation of primary prostate cancer using 68gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology[J]. BJU Int, 2020, 126(1): 83−90. DOI: 10.1111/bju.14858. [13] Evangelista L, Zattoni F, Cassarino G, et al. PET/MRI in prostate cancer: a systematic review and meta-analysis[J]. Eur J Nucl Med Mol Imaging, 2021, 48(3): 859−873. DOI: 10.1007/s00259-020-05025-0. [14] Liu FY, Sheng TW, Tseng JR, et al. Prostate-specific membrane antigen (PSMA) fusion imaging in prostate cancer: PET-CT vs. PET-MRI[J]. Br J Radiol, 2022, 95(1131): 20210728. DOI: 10.1259/bjr.20210728. [15] Herlemann A, Wenter V, Kretschmer A, et al. 68Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer[J]. Eur Urol, 2016, 70(4): 553−557. DOI: 10.1016/j.eururo.2015.12.051. [16] Baas DJH, Schilham M, Hermsen R, et al. Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection[J]. Prostate Cancer Prostatic Dis, 2022, 25(1): 65−70. DOI: 10.1038/s41391-021-00452-y. [17] Franklin A, Yaxley WJ, Raveenthiran S, et al. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer[J]. BJU Int, 2021, 127(1): 71−79. DOI: 10.1111/bju.15134. [18] Abufaraj M, Grubmüller B, Zeitlinger M, et al. Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT (MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy[J]. Eur J Nucl Med Mol Imaging, 2019, 46(10): 2169−2177. DOI: 10.1007/s00259-019-04361-0. [19] Kimura S, Abufaraj M, Janisch F, et al. Performance of [68Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis[J]. Prostate Cancer Prostatic Dis, 2020, 23(1): 1−10. DOI: 10.1038/s41391-019-0156-z. [20] Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study[J]. Lancet, 2020, 395(10231): 1208−1216. DOI: 10.1016/S0140-6736(20)30314-7. [21] Uprimny C, Svirydenka A, Fritz J, et al. Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy[J]. Eur J Nucl Med Mol Imaging, 2018, 45(11): 1873−1883. DOI: 10.1007/s00259-018-4048-6. [22] Fraum TJ, Ludwig DR, Kim EH, et al. Prostate cancer PET tracers: essentials for the urologist[J/OL]. Can J Urol, 2018, 25(4): 9371−9383[2023-02-07]. https://www.canjurol.com/abstract.php?ArticleID=&version=1.0&PMID=30125515. [23] Karagiannis V, Wichmann V, Saarinen J, et al. Radiotherapy treatment modification for prostate cancer patients based on PSMA-PET/CT[J/OL]. Radiat Oncol, 2022, 17(1): 19[2023-02-07]. https://ro-journal.biomedcentral.com/articles/10.1186/s13014-022-01989-5. DOI: 10.1186/s13014-022-01989-5. [24] Calais J, Kishan AU, Cao MS, et al. Potential impact of 68Ga-PSMA-11 PET/CT on the planning of definitive radiation therapy for prostate cancer[J]. J Nucl Med, 2018, 59(11): 1714−1721. DOI: 10.2967/jnumed.118.209387. [25] Hoffmann MA, Wieler HJ, Baues C, et al. The impact of 68Ga-PSMA PET/CT and PET/MRI on the management of prostate cancer[J]. Urology, 2019, 130: 1−12. DOI: 10.1016/j.urology.2019.04.004. [26] Mingels C, Bohn KP, Rominger A, et al. Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2022, 49(7): 2436−2444. DOI: 10.1007/s00259-022-05693-0. [27] Beheshti M, Manafi-Farid R, Geinitz H, et al. Multiphasic 68Ga-PSMA PET/CT in the detection of early recurrence in prostate cancer patients with a PSA level of less than 1 ng/mL: a prospective study of 135 patients[J]. J Nucl Med, 2020, 61(10): 1484−1490. DOI: 10.2967/jnumed.119.238071. [28] Ferrari M, Treglia G. 18F-PSMA-1007 PET in biochemical recurrent prostate cancer: an updated meta-analysis[J]. Contrast Media Mol Imaging, 2021: 3502389. DOI: 10.1155/2021/3502389. [29] Huo HS, Shen SR, He D, et al. Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies[J]. Prostate Cancer Prostatic Dis, 2023, 26(1): 16−24. DOI: 10.1038/s41391-022-00581-y. [30] Manafi-Farid R, Ranjbar S, Jamshidi Araghi Z, et al. Molecular imaging in primary staging of prostate cancer patients: current aspects and future trends[J/OL]. Cancers (Basel), 2021, 13(21): 5360[2023-02-07]. https://www.mdpi.com/2072-6694/13/21/5360. DOI: 10.3390/cancers13215360. [31] Zamboglou C, Carles M, Fechter T, et al. Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference[J/OL]. Theranostics, 2019, 9(9): 2595−2605[2023-02-07]. https://www.thno.org/v09p2595.htm. DOI: 10.7150/thno.32376. [32] Papp L, Spielvogel CP, Grubmüller B, et al. Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga]Ga-PSMA-11 PET/MRI[J]. Eur J Nucl Med Mol Imaging, 2021, 48(6): 1795−1805. DOI: 10.1007/s00259-020-05140-y. [33] Solari EL, Gafita A, Schachoff S, et al. The added value of PSMA PET/MR radiomics for prostate cancer staging[J]. Eur J Nucl Med Mol Imaging, 2022, 49(2): 527−538. DOI: 10.1007/s00259-021-05430-z. [34] 中华医学会泌尿外科学分会, 中国前列腺癌研究协作组. 前列腺穿刺中国专家共识(2022年版)[J]. 中华泌尿外科杂志, 2022, 43(11): 801−806. DOI: 10.3760/cma.j.cn112330-20221111-00005.
Chinese Prostate Cancer Consortium, Chinese Urological Association. Chinese expert consensus on prostate biopsy (2022 edition)[J]. Chin J Urol, 2022, 43(11): 801−806. DOI: 10.3760/cma.j.cn112330-20221111-00005.[35] Satapathy S, Singh H, Kumar R, et al. Diagnostic accuracy of 68Ga-PSMA PET/CT for initial detection in patients with suspected prostate cancer: a systematic review and meta-analysis[J]. AJR Am J Roentgenol, 2021, 216(3): 599−607. DOI: 10.2214/AJR.20.23912. [36] Zhang LL, Li WC, Xu Z, et al. 68Ga-PSMA PET/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study[J]. Eur J Nucl Med Mol Imaging, 2021, 48(2): 483−492. DOI: 10.1007/s00259-020-04863-2. [37] Liu C, Liu TL, Zhang ZY, et al. 68Ga-PSMA PET/CT combined with PET/ultrasound-guided prostate biopsy can diagnose clinically significant prostate cancer in men with previous negative biopsy results[J]. J Nucl Med, 2020, 61(9): 1314−1319. DOI: 10.2967/jnumed.119.235333. [38] Qiu DX, Li J, Zhang JW, et al. Dual-tracer PET/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study[J]. Eur J Nucl Med Mol Imaging, 2022, 49(8): 2821−2832. DOI: 10.1007/s00259-021-05636-1. [39] Karl A, Konety B. Androgen deprivation therapy for prostate cancer: indications, contraindications and possible consequences[J/OL]. F1000 Med Rep, 2009, 1: 2[2023-02-07]. https://connect.h1.co/prime/reports/pubmed/20948762. DOI: 10.3410/M1-2. [40] Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer[J]. N Engl J Med, 2021, 385(12): 1091−1103. DOI: 10.1056/NEJMoa2107322. [41] Satapathy S, Mittal BR, Sood A, et al. 177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial[J]. Eur J Nucl Med Mol Imaging, 2022, 49(5): 1754−1764. DOI: 10.1007/s00259-021-05618-3. [42] Hofman MS, Violet J, Hicks RJ, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study[J]. Lancet Oncol, 2018, 19(6): 825−833. DOI: 10.1016/S1470-2045(18)30198-0.
计量
- 文章访问数: 4608
- HTML全文浏览量: 4205
- PDF下载量: 17